Lung Cancer Pill Cuts Risk of Death by Half, Study Finds
A pill taken once a day cuts the risk of dying from lung cancer by half, according to "thrilling" and "unprecedented" results from a decade-long global study. Taking the drug osimertinib after surgery dramatically reduced the risk of patients dying by 51%, results presented at the world's largest cancer conference showed...
Everyone in the trial had a mutation of the EGFR gene, which is found in about a quarter of global lung cancer cases, and accounts for as many as 40% of cases in Asia. An EGFR mutation is more common in women than men, and in people who have never smoked or have been light smokers. Speaking in Chicago, [Dr Roy Herbst, the deputy director of Yale Cancer Center and lead author of the study] said the "thrilling" results added huge weight to earlier findings from the same trial that showed the pill also halves the risk of a recurrence of the disease... Not everyone diagnosed with lung cancer is tested for the EGFR mutation, which needs to change, Herbst said, given the study's findings...
After five years, 88% of patients who took the daily pill after the removal of their tumour were still alive, compared with 78% of patients treated with a placebo. Overall, there was a 51% lower risk of death for those who received osimertinib compared with those who received placebo. The survival benefit "was observed consistently" in an analysis across all study subgroups, including those with stage one, stage two and stage three lung cancer. Chemotherapy had been given to 60% of those in the study, and the survival benefit of osimertinib was seen regardless of whether prior chemotherapy was received.